HERBERT J. CONRAD - 16 Jun 2022 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
Director
Signature
/s/ Samuel B. Martin, attorney-in-fact for Herbert J. Conrad
Issuer symbol
CLDX
Transactions as of
16 Jun 2022
Net transactions value
$0
Form type
4
Filing time
17 Jun 2022, 16:08:27 UTC
Previous filing
02 Nov 2021
Next filing
16 Nov 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Non-Qualified Stock Option (right to buy) Award $0 +13,600 $0.000000 13,600 16 Jun 2022 Common Stock 13,600 $22.48 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.